13126994375
English
About
Never forget the original intention and build a new service system capability
Love only health
Focusing on the Full Life Cycle 
Health Management of Families
Hangzhou Xinsheng Era Technology Co., Ltd. is led by the research and development of cell drugs, based on cell storage, cell preparation, and derivative production. Driven by four core patented cell technologies including mesenchymal stem cells, NK cells, fibroblasts, and exosomes, combined with traditional Chinese medicine long-term management and functional medicine, we are committed to preventing diseases and keeping people in a healthy state, focusing on family life cycle health management.

Relying on the Aiwei Cell Factory, which has invested over 600 million yuan and covers an area of 80 acres (38000 square meters), and with the dual qualifications of Hangzhou Regional Cell Preparation Center and National High tech Enterprise, it has built a solid foundation of hard power and is approved as a pilot zone for the life and health industry by the International Cooperation Center of the National Development and Reform Commission.

Mesenchymal stem cells can repair and regenerate joint injury, chronic inflammation, diabetes and other metabolic abnormalities.
NK cells focus on enhancing defense against tumors, viral infections, and immune suppression.
Fibroblasts are used to achieve anti-aging rejuvenation for skin sagging, wrinkles, and dullness, and are integrated with compliant medical resources to form a comprehensive support system.

Strictly adhere to quality control and digital traceability throughout the process, practice the core values of "professionalism, safety, and long-term effectiveness", and build a technological barrier for family health.
Corporate Culture
Professional | Security | Technology | Guardian
The first cell industry university research base in Zhejiang Province
In 2016, Hangzhou Aiwei Life Technology Co., Ltd. was established to invest in the construction of the first cell engineering and regenerative medicine industry university research base in Zhejiang Province - Aiwei (International) Cell Engineering and Regenerative Medicine Industry University Research Base. The project covers an area of 58.12 acres, with a first phase construction area of approximately 38000 square meters. The cell preparation center, cell quality control center (GMP), biological resource storage center, and independent positive cell preparation workshop (GMP) have all been put into use.
The construction of the preparation center strictly follows
  • Good Manufacturing Practice for Drugs
  • Design Specification for Cleanrooms in the Pharmaceutical Industry
  • Self discipline Specification for Quality Management of Stem Cell Preparation
  • Quality Management Standards for Cell Banks
Having 11 GMP compliant B+A-level preparation laboratories
  • Nearly 50 rooms of other levels
International Quality Management System
  • Compliant with ISO9001 quality system certification.
  • Compliant with ISO45001 environmental management system and ISO14001 occupational health and safety management system certification.
  • High standard screening of cell sources, testing more than 10 virus indicators according to international standards, and excluding samples with genetic disease background and family history background.
  • Strictly follow the national "Management Measures for Stem Cell Clinical Research", "Guiding Principles for Cell Therapy Products", and the implementation standards of quadruple sample testing, quality testing, release testing, and review testing.
  • The internal toxicity index of the implementation standard is as strict as 0.25EU, which is 20 times stricter than the European standard (the current EU standard is 5EU).
  • The preparation adopts an independent negative pressure laboratory to handle positive and suspected infection samples separately.
  • The quality control adopts an independent negative pressure laboratory and is certified by BSL-2 level biosafety laboratory.
Qualifications and Honors
  • Academician Wu Zuze Workstation
  • 2021
    Hangzhou Regional Cell Preparation Center (Pilot)
  • PICC | Aiwei Life Technology (Hangzhou Regional Cell Preparation Center)
  • 2021
    Tonglu County Comprehensive Cell Preparation Center (Cell Bank)
  • 2019
    Hangzhou, China Tonglu (International) Pilot Zone for Life and Health Industry
  • 2022
    High tech enterprises
  • 2024
    Director Certificate
  • 2023
    Certificate of Municipal Enterprise High tech R&D Center
  • 2021
    A BMP-2 activator and its application in inducing differentiation of stem cells
  • 2021
    Drug combination containing K cells and its use in treating cancer
  • 2020
    A method for identifying liver cancer stem cells
  • 2021
    A transport box for stem cell collection
  • 2021
    A transport box for stem cell collection
  • 2021
    A stem cell collection and transportation box
  • 2022
    A collection device for stem cells
  • 2022
    A cryopreservation device for stem cells
  • 2021
    A culture room for stem cell cultivation and detection
  • 2022
    A storage device for immune cells
  • 2022
    A transport device for immune cells
  • 2021
    A new type of stem cell activity detection kit
  • 2021
    A new type of stem cell activity detection kit
  • 2021
    A new type of deep low-temperature transport box for stem cells
  • 2024
    Environmental Management System Certification Certificate
  • 2024
    Environmental Management System Certification Certificate
  • 2024
    quality management system certification
  • 2024
    Occupational Health and Safety Management System Certification
  • 2024
    Occupational Health and Safety Management System Certification
Development History
Family health service system, suitable health intervention plan for the whole family
  • 2026
  • 2016
  • 2017
  • 2018
  • 2019
  • 2020
  • 2021
  • 2022
  • 2023
  • 2024
  • 2025
  • Site Map
  • 2026
    Hangzhou Aiwei Life Technology Co., Ltd. was officially established
  • 2016
    The establishment meeting of the Standards Working Committee of the China Pharmaceutical Biotechnology Association was held at the launch conference of the Self discipline Norms for Quality Management of Cell Preparation
  • 2017
    The permanent venue for the ten major progress selection press conference has been established
  • 2018
    Hangzhou Aiwei Cell and Regenerative Medicine Industry University Research Base starts construction
  • 2019
    Signed at Academician Wu Zuze Workstation
    Influence: The First National Health Industry Pilot Zone in the Yangtze River Delta
  • 2020
    Donated materials for the epidemic
  • 2021
    In 2021, Aiwei was approved as the "Hangzhou Regional Cell Preparation Center"
  • 2022
    Hangzhou Enterprise High tech Research and Development Center
  • 2023
    The national standard drafted by Hangzhou Aiwei Life Technology Co., Ltd. has been officially released!
    Leaders from the Science and Education Department of Hangzhou Municipal Health Commission and Hangzhou First People's Hospital visited Hangzhou Aiwei Life Technology Co., Ltd. for research
    Hangzhou Aiwei Life Technology Co., Ltd. signed a cooperation intention agreement with Hangzhou First People's Hospital to jointly build research-oriented wards
    Fang Suping, Vice Chairman of Guiqing National Pharmaceutical Biotechnology Association and Director of Hangzhou Aiwei Life Technology Co., Ltd., attended the 30th anniversary commemoration conference of the association.
  • 2024
    Influence · "China · Fuchun Mountain" Conference
  • 2025
    The State Council has issued regulations to unify the clinical application standards and approval supervision of stem cells, changing the previous situation of "inconsistent standards and fragmented management"
    The New Era is officially established, opening a new chapter of development with the power of marketization
    Aiwei Life Technology supports Hangzhou Biological Sample Bank, driving pharmaceutical innovation ecology with cell technology
  • Site Map